Last month CSL Behring announced its commitment to donate additional clotting factor VIII product worth approximately $500,000 to the World Federation of Hemophilia (WFH). The donations, which will be made as part of WFH’s Global Alliance for Progress (GAP) program, will go toward treatment in South America, Thailand, the Philippines, parts of Eastern Europe, parts of the Middle East, and in Tunisia. The purpose of the GAP program, established in 2003, is to improve the diagnosis and treatment of hemophilia and other bleeding disorders in developing countries.
“The WFH relies on product donations to help introduce clotting factor concentrates in developing countries and these donations serve as a catalyst for improving care,” said Claudia Black, Chief Executive Officer of WFH. “We are grateful to our industry partners such as CSL Behring, who provide, among other resources, valuable and life-saving medicine, including this most recent donation of coagulation factor.”
Source: CSL Behring press release dated February 16, 2011